Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-22
2011-03-22
Lukton, David (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S331000
Reexamination Certificate
active
07910553
ABSTRACT:
A method of treating a patient for a condition wherein the bioactive agent of choice is DRUG, wherein DRUG is a substrate that is effluxed by the P-gp transporter, is provided, the method comprising administering to the patient an effective amount of a compound of formula (I):in-line-formulae description="In-line Formulae" end="lead"?DRUG-X—Y(n)—Z(n′)—Z′(n″)—R (I)in-line-formulae description="In-line Formulae" end="tail"?wherein each X, Y, Z, and Z′ is independently Met, Val, Thr, Tyr, Trp, Ser, Ala, or Gly; R is H or an amino-protecting group; n is 1, and each n′, or n″ is independently 0 or 1; or a pharmaceutically acceptable salt thereof, with the proviso that DRUG is not acyclovir or ganciclovir and that DRUG is non-peptidyl.
REFERENCES:
patent: 5405850 (1995-04-01), Blumenkopf
patent: 7214663 (2007-05-01), Bebbington et al.
patent: 7214664 (2007-05-01), Mitra et al.
patent: 7553812 (2009-06-01), Mitra
patent: 2005/0043246 (2005-02-01), Mitra
patent: 2006/0135438 (2006-06-01), Mitra et al.
patent: 2009/0082566 (2009-03-01), Mitra
patent: 2009/0149482 (2009-06-01), Mitra et al.
patent: WO 03/048190 (2003-06-01), None
“U.S. Appl. No. 12/194,248 ,Non-Final Office Action mailed Oct. 5, 2009”, 8 Pgs.
“U.S. Appl. No. 10/854,533, Final Office Action mailed Nov. 1, 2007”, 8 pgs.
“U.S. Appl. No. 10/854,533, Non-Final Office Action mailed Sep. 8, 2006”, 6 pgs.
“U.S. Appl. No. 10/854,533, Response filed Dec. 1, 2006 to Non-Final Office Action mailed Sep. 8, 2006”, 9 pgs.
“U.S. Appl. No. 10/854,533, Response filed Mar. 28, 2007 to Restriction Requirement mailed Feb. 26, 2007”, 8 pgs.
“U.S. Appl. No. 10/854,533, Response filed Jun. 27, 2007 to Non-Final Office Action mailed Feb. 26, 2007”, 8 pgs.
“U.S. Appl. No. 10/854,533, Response filed Jun. 30, 2006 to Restriction Requirement mailed May 16, 2006”, 2 pgs.
“U.S. Appl. No. 10/854,533, Restriction Requirement mailed Feb. 26, 2007”, 7 pgs.
“U.S. Appl. No. 10/854,533, Restriction Requirement mailed May 16, 2006”, 9 pgs.
“U.S. Appl. No. 11/285,754, Non-Final Office Action mailed Jul. 25, 2006”, 8 pgs.
“U.S. Appl. No. 11/285,754, Notice of Allowance mailed Dec. 26, 2006”, 5 pgs.
“U.S. Appl. No. 11/285,754, Preliminary Amendment filed Feb. 8, 2006”, 3 pgs.
“U.S. Appl. No. 11/285,754, Response filed Nov. 21, 2006 to Non-Final Office Action mailed Jul. 25, 2006”, 10 pgs.
“U.S. Appl. No. 11/285,754, Response filed Jun. 20, 2006 to Restriction Requirement mailed May 26, 2006”, 2 pgs.
“U.S. Appl. No. 11/285,754, Restriction Requirement mailed May 26, 2006”, 7 pgs.
“International Application Serial No. PCT/US02/338846, International Preliminary Examination Report Dec. 20, 2004”, 6 pgs.
“International Application Serial No. PCT/US02/338846, International Search Report Jul. 21, 2003”, 5 pgs.
Colla, Leon , et al., “Synthesis and antiviral activity of water-soluble esters of acyclovir [9[(2-hydroxyethoxy)methyl]guanine]”,Journal of Medicinal Chemistry, 26(4), (Apr. 1983),602-4.
Dey, Surajit , et al., “Molecular Evidence and Functional Expression of P-Glycoprotein (MDR1) in Human and Rabbit Cornea and Corneal Epithelial Ceil Lines”,Investigative Ophthalmology&Visiual Science, 44(7), (Jul. 2003),2909-2918.
Fricker, Gert , et al., “Modulation of Drug Transporters at the Blood-Brain Barrier”,Pharmacology, 70(4), (2004),170-176.
Gao, Hongwu , et al., “Regioselective synthesis of various prodrugs of ganciclovir”,Tetrahedron Letters, 41(8), (2000),1131-1136.
Gaucher, Berandere , “Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity”,Org Biomol Chem., 2(3), (2004),345-57.
Han, H. , “5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter”,Pharmaceutical Research, 15, (1998),1154-1159.
Irvine, Jennifer D., et al., “MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening”,Journal of Pharamaceutical Sciences, 88(1), (Jan. 1999),28-33.
Jain, R. , et al., “Circumventing P-glycoprotein-mediated cellular efflux of quinidine by prodrug derivatization”,Molecular Pharmaceutics, 1(4), (Jul.-Aug. 2004),290-299.
Jain, Ritesh , et al., “Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification”,International Journal of Pharmaceutics, 303(1-2), (2005),8-19.
Lee, Vincent H., “Membrane transporters”,European Journal of Pharmaceutical Sciences, 11(Suppl 2), (Oct. 2000),S41-50.
Rouquayrol, Marielle , et al., “Transepithelial transport of prodrugs of the HIV protease inhibitors saquinavir, indinavir, and nelfinavir across Caco-2 cell monolayers”,Pharmacuetical Research, 19(11), (Nov. 2002),1704-1712.
Vierling, Pierre , et al., “Prodrugs of HIV Protease Inhibitors”,Current Pharmaceutical Design, 9(22), (2003),1755-1770.
“U.S. Appl. No. 10/854,533 response to Final Office Action mailed Nov. 1, 2007.”, 19 pgs.
“U.S. Appl. No. 10/854,533 Notice of Allowance mailed Jul. 3, 2008.”, 11 pgs.
Jain Ritesh
Majumdar Soumyajit
Mitra Ashim K.
Nashed Yasser
Lukton David
Stinson Morrison & Hecker LLP
The Curators of the University of Missouri
LandOfFree
Peptidyl prodrugs that resist P-glycoprotein mediated drug... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptidyl prodrugs that resist P-glycoprotein mediated drug..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidyl prodrugs that resist P-glycoprotein mediated drug... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2639783